富祥藥業(300497.SZ):擬不超3.86億元投建年產2萬噸硫酰氟和1萬噸雙氟磺酰亞胺鋰項目
格隆匯5月22日丨富祥藥業(300497.SZ)公佈,公司於2023年5月22日召開了第四屆董事會第十次會議,審議通過了《關於投資建設年產2萬噸硫酰氟和1萬噸雙氟磺酰亞胺鋰項目的議案》,同意公司在全資子公司景德鎮富祥生命科技有限公司(簡稱“富祥科技”)投資建設年產2萬噸硫酰氟和1萬噸雙氟磺酰亞胺鋰項目,項目計劃總投資不超過3.86億元。
項目建設週期為2.5年,分兩期建設,其中一期建設年產2000噸硫酰氟和1000噸雙氟磺酰亞胺鋰。(項目建設週期及投資總額以實際投資建設情況為準)。
項目滿產後年新增收入18.37億元,年新增淨利潤3.06億元,税後財務內部收益率48.02%,税後投資回收期(不含建設期)為3.1年。前述數據為公司初步估計數據,不構成盈利預測,亦不構成業績承諾。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.